[Subcutaneous emphysema of unusual extent]

S Besier1, T M Bingold, F Walcher

  • 1Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Klinikum der Johann Wolfgang Goethe-Universität, 60596, Frankfurt am Main. s.besier@em.uni-frankfurt.de

Insights

Streptococcus agalactiae, a cause of neonatal meningitis, can lead to severe invasive disease like necrotizing fasciitis and toxic shock syndrome in adults. Early intervention is crucial for patient outcomes.

Area of Science:

  • Infectious Diseases
  • Clinical Microbiology
  • Critical Care Medicine

Background:

  • Streptococcus agalactiae (Group B Streptococcus) is a primary cause of meningitis and septicemia in neonates.
  • Invasive infections by S. agalactiae are increasingly recognized in nonpregnant adults, particularly those with chronic conditions.
  • Risk factors include chronic diseases and immunodeficiency, predisposing individuals to Group B Streptococcal disease.

Observation:

  • This case report details a severe necrotizing fasciitis (NF) with streptococcal toxic shock-like syndrome (STSS).
  • The patient was a 76-year-old diabetic with subcutaneous emphysema.
  • The causative agent was identified as S. agalactiae, serotype V.

Findings:

  • The patient experienced a fulminant course of necrotizing fasciitis and streptococcal toxic shock-like syndrome.
  • S. agalactiae serotype V was identified as the pathogen responsible for the invasive infection.
  • Subcutaneous emphysema was noted in the context of this severe invasive S. agalactiae infection.

Implications:

  • Clinicians must maintain a high index of suspicion for invasive S. agalactiae infections in adults, especially those with risk factors like diabetes and subcutaneous emphysema.
  • Prompt diagnosis and management, including early surgical intervention, antimicrobial therapy, and intensive care, are critical for improving outcomes in patients with NF and/or STSS.
  • This case highlights the potential for S. agalactiae to cause life-threatening infections in the elderly population.

Related Concept Videos

Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Atelectasis II: Pathophysiology01:10

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...